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1. Introduction
1.1. History of platelets and their association with cancer
In 1865, Armand Trousseau observed several cases of severe blood clotting in patients with
malignancy [1] but was unable to speculate on the underlying mechanism. In 1882, Bizzozero
first demonstrated that blood platelets, or thrombocytes, adhered to damaged blood vessels
and hypothesised that these blood components played a central role in haemostasis and
experimental thrombosis [2]. Subsequently, Riess reported an association between thrombo‐
cytosis (defined as a platelet count of >400x109/ L of blood) and cancer death [3]. Almost a
century later, these preliminary observations were revisited and confirmed [4, 5], initiating a
renewed interest in a potential role for platelets in cancer metastasis, invasion and angiogenesis
[6-10]. In this chapter, we will explore the evidence demonstrating a wider remit for platelets
than simple haemostasis and thrombosis. We will review the data suggesting that platelets
facilitate circulating cancer cells to traverse physiological and immunological obstacles and
establish as solid tumours in remote places, where they enable a bespoke blood supply. In
addition, we will explore the complex molecular mechanisms that underlie the platelet-tumour
cell interactions.
2. Platelet biology in haemostasis and cancer
The role of platelets in haemostasis and thrombosis is well known. Platelets survey the blood
vessels for evidence of damage. Upon detection, platelets undergo a rapid but highly regulated
activation which results in dramatic shape change, adhesion to the exposed sub-endothelial
matrix, secretion of important effectors from dense granules and/or alpha-granules, formation
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of a haemostatic platelet aggregate and activation of the coagulation cascade. All of these
processes lead to reinforcement of the platelet plug in closing the breech in the vessel wall [11].
Thus, the currently accepted role for platelets is to contribute to haemostasis by their physio‐
logical ability to maintain the structural integrity of the blood vessels.
The role of platelets in cancer metastases is less well known. However, numerous experimental
studies have shown that thrombocytopenia (defined as a platelet count of <100x109/L blood)
induced in tumour-bearing mice, effectively reduces tumour dissemination and tumour
growth [6, 17]. Moreover, thrombocytosis may be an indicator of an advanced stage of cancer
and is often associated with poor prognosis. Thus, platelets appear to exert a pro-metastatic
function, enabling tumour development.
Metastasis is the dissemination of cancer cells from the primary tumour mass to distant organs
and occurs predominantly through the blood stream [12]. It is an intricate multi-step cascade
during which cancer cells intravasate from the primary site into the blood vessels, circulate in
the blood towards distant anatomical sites, adhere to the luminal wall of micro-vessels
(arterioles and capillaries) and penetrate into the surrounding tissue (extravasation) to
eventually colonize it [13]. Survival of the newly relocated tumour foci depends on the
subsequent establishment of a novel blood supply to support tumour growth, a process termed
angiogenesis [14]. Metastasis is responsible for as much as 90% of cancer associated mortality
[15].
The pro-metastatic activity of platelets can be explained as the pathological capability to prolong
tumour cell survival in the circulation and in the new metastatic location. Survival of circu‐
lating tumour cells (CTCs) in the circulation is achieved by protecting them from immune
destruction, facilitating their adhesion to the vascular endothelium or enabling extravasation
of the tumour cells to secondary sites. Moreover, platelets play a role in enabling angiogenesis
to provide a necessary blood supply for a growing tumour mass [16-19, 20].
In normal circulation within intact vasculature, most platelets do not undergo significant
interactions with the endothelial surface during their entire lifetime. The quiescent state of
platelets is protected by the presence of extrinsic regulators, such as nitric oxide (NO) and
prostacyclin (PGI2), produced continuously by intact endothelial cells. Moreover, the presence
of potential platelet activators such as collagen, adenosine diphosphate (ADP) and thrombin
are tightly regulated in the bloodstream. Only strong biological signals such as the exposure
of the sub-endothelial matrix components (VWF, collagen, fibrinogen, laminin, fibronectin)
following endothelial damage or the generation of thrombin via the coagulation cascade will
permit platelet activation to enable a haemostatic or a thrombotic response. Platelets adhere
to sub-endothelial molecules via their surface receptors for von Willebrand Factor, VWF (GPIb/
IX/V), collagen (α2β1 and GPVI), fibrinogen (αIIbβ3), fibronectin (α5β1) and laminin (α6β1),
resulting in platelet capture, activation, shape change and release of secretory granules. The
relative contribution of each receptor-ligand interaction is influenced by blood flow condition,
with GpIb-VWF interplay prevailing under high shear conditions observed in arterioles/
stenotic arteries [21]. Activated platelets rapidly secrete and produce a number of soluble
molecules, mainly ADP and thromboxane (TXA2), triggering activation of surrounding
platelets leading to the formation of a platelet-rich clot. Moreover, activated platelets express
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negatively charged surface phospholipids that contribute to localised coagulation leading to
thrombin generation. Thrombin then further activates platelets via protease-activated recep‐
tors -1 (PAR-1), -4 (PAR-4) and GPIb-IX-V [22-25] and also enzymatically converts fibrinogen
into fibrin [26]. The binding of fibrin results in further reinforcement of the existing platelet
plug and of its anchorage to the site of vascular injury [21]. Figure 1 shows an overview of
platelet activation responses to wounding and cancer metastasis.
Figure 1. Differentiating platelet activity in haemostasis and cancer. Blue Box: In physiological condition platelets circu‐
late in the blood stream in a quiescent state. Prostacyclin I2 (PGI2) and nitric oxide (NO) are the main soluble mediators
through which the endothelium inhibits platelet reactivity. Yellow Box: In response to endothelial injury, highly throm‐
bogenic proteins such as von Willebrand factor (VWF) and collagen are exposed, which synergistically induce platelet
activation and haemostatic plug formation. Fibrin consolidates the platelet plug while newly formed blood vessels (an‐
giogenesis) provide nutrients to inflammatory cells and clear cell debris. Red Box: Circulating cancer cells (CTC) acti‐
vate and aggregate platelets via paracrine and/or juxtacrine signals to ensure their survival in the bloodstream, and to
permit extravasation and proliferation at the metastatic site. Fibrin supports tumour inflammation and provides im‐
portant scaffolding for tumour cell attachment to the endothelium. Newly formed vessels guarantee nutrients and oxy‐
gen for tumour growth and survival.
Importantly, platelet activation, aggregation and secretion, are also triggered in a carcinogenic
microenvironment [6, 9, 27] and serve to enable tumour metastasis. The first experimental
observation of platelet involvement in cancer metastasis dates back to 1968 when Gasic and
colleagues demonstrated an anti-metastatic effect associated with thrombocytopenia in mouse
models [6]. Subsequently, several in vitro and in vivo experimental models provided direct
demonstrations of the profound pro-survival influence that platelet activation exerts on three
critical stages during blood borne metastasis:
1. cancer dissemination through the blood (haematogenous spread);
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2. tissue invasion or extravasation from the vasculature at the metastatic site and
3. Tumour angiogenesis and tumour blood vessels stability.
2.1. Platelets enable cancer cell dissemination during haematogenous spread
During their migration through the bloodstream, circulating cancer cells (CTCs) are exposed
to an unfavourable environment, characterised by shear forces and innate immune cytotoxic‐
ity. In order to escape immune recognition and overcome shear forces, CTCs in the blood‐
stream attract an entourage of platelets and use them as a cellular shield for their survival [18,
28]. Evidence that platelets prevent natural killer cells (NK) from destroying CTCs, comes from
both in vivo and in vitro studies. Platelet-depletion in mice causes a reduction in tumour
colonization when compared to mice with normal platelet counts [29]. In addition, the ability
of NK cells to lyse the tumour cells in vitro is directly correlated with platelet density [29].
Palumbo and colleagues subsequently demonstrated that platelet-fibrin deposits form a cloak
around B16-F10 melanoma cells helping to camouflage the tumour cells to enable them to
escape immune recognition and elimination [30]. The mesh of fibrin, induced by tissue factor
on the surface of CTCs, envelops the cancer cells [18, 31] permitting them to evade recognition
by NK cells [32, 33]. In addition, the coat of platelets enables a mechanism of molecular mimicry
resulting in the acquisition of platelet-derived major histocompatibility complex (MHC-I) by
cancer cells [34]. Moreover, platelet derived transforming growth factor β (TGFβ) and platelet
derived growth factor (PDGF) can impede NK immune surveillance by down-regulating the
NK cell activating immune-receptor (NKG2D) [35] and NK cell PDGF receptor- expression
[36]. Thus platelets enhance CTC survival, permitting them to traverse the blood vessels to
establish a secondary locations.
2.2. Platelets support cancer cell extravasation
In order to leave the circulation and metastasize, cancer cells must adhere to the microvascu‐
lature of a target organ and penetrate the surrounding tissue [37]. As early as 1985, electron
micrographs showed B16 melanoma cells trapped in an intricate network of platelets and fibrin
at the lung vasculature site [38]. Indeed, under in vitro flow conditions, platelets facilitate
tumour cells adhesion to enable the cancer cells to tether and arrest to the subendothelium [39,
40] by using platelet P-selectin and αIIbβ3 as potential bridging molecules. Tethering and
adhesion of colon carcinoma (LS174T, COLO205, and HCT-8) and melanoma cells (M21, M397,
M501 and M537) to the subendothelium can be prevented by antagonism of P-selectin or
αIIbβ3, on platelet surfaces [39-41]. Furthermore, platelets adhering to CTCs are activated to
release growth factors (including vascular endothelium growth factor (VEGF), TGFβ, and
PDGF) and proteases of the matrix metalloprotease (MMP) class at sites of adhesion to the
endothelium [42-44]. Once released, platelet-derived cytokines enhance endothelial growth
while MMPs will degrade specific component of the extracellular matrix (ECM) encouraging
vascular permeability and extravasation of tumour cells, as well as the release of growth factors
sequestered in the ECM [45].
Extravasation is also supported by platelet-derived nucleotides. Munc13-4 deficient mice,
whose platelets lack the ability to secrete dense granule components such as ADP and ATP,
or mice deficient in the P2Y2-ATP receptor on endothelial cells, demonstrate a significant
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reduction in metastasis in mouse models of melanoma (B16) and breast carcinoma (LCC) [20].
Thus, platelet-bound adhesive molecules and platelet derived soluble molecules synergisti‐
cally help cancer cells to traverse the endothelial cell barriers, penetrate the parenchyma and
establish new lesions.
2.3. Platelets promote tumour angiogenesis and safeguard vascular integrity
The assembly of a new vascular network (angiogenesis) is of central importance to the growth
of solid tumours beyond 2-3 mm [46]. The role of platelets in angiogenesis and be found in
recent comprehensive reviews [14, 47]. An intimate association with the circulation is required
for the tumour to acquire necessary nutrients, to shed metabolic waste products and to sustain
further tumour growth and invasion [43, 48]. Interestingly, tumour blood vessels display
remarkable morphological abnormalities involving permeability and leakiness, and excessive
and haphazard branching [45, 49]. This vessel morphology permits the access of CTCs to the
circulation, favouring contacts with platelets which, in turn, can function as source of pro-
angiogenic factors at the metastatic niche and contribute to tumour survival and progression
[50]. Indeed, platelets can stimulate endothelial cell proliferation and augment the formation
of capillaries-like tubes in vitro [51] and angiogenesis in vivo [17, 52, 53]. Brock’s finding that
tumour-derived vascular endothelial growth factor (VEGF), a molecule that enables angio‐
genesis by stimulating endothelial cells proliferation and migration, can stimulate endothelial
cells to expose VWF is noteworthy [54]. It has in fact been speculated that the release of platelet
binding or activating molecules, such as VWF, may favour platelet adhesion to the vascular
wall with a consequent activation and release of further pro-angiogenic molecules [50].
Platelets are recognised as major physiological transporters of VEGF in blood of healthy
subjects and patients with breast and colorectal cancer [50, 55-59]. The possible rationale
underlying this phenomenon became apparent when the ability of platelets to actively and
selectively sequester tumour-derived angiogenesis regulators in a carcinogenic microenvir‐
onment was shown [60, 61]. Therefore, it was not surprising to observe that platelets isolated
from tumour-bearing mice and activated with ADP could induce angiogenesis more efficiently
than platelets obtained from cancer-free mice [62].
In addition to VEGF, platelets are carriers of many crucial regulators of angiogenesis (pro- and
anti- angiogenic factors), which can be released, in a selective fashion according to the nature
of the stimulus [19, 63, 64], a concept that is still somewhat controversial. However in this
context, MCF-7 breast cancer cells can orchestrate the preferential release of pro-angiogenic
molecules (e.g. VEGF), but not of the anti-angiogenic counterpart (e.g. endostatin), from
platelet α-granules, to induce angiogenesis in vitro [19]. Interestingly, treatment of human
platelets with aspirin (COX-1 inhibitor) or antibodies against αIIbβ3 prior to exposure to breast
cancer cells has been shown to inhibit the release of pro-angiogenic factors in vitro [19, 65, 66].
In addition to storage and release of angiogenic regulators, platelets can also contribute to
maintaining tumour vessel homeostasis by protecting tumour-vasculature from haemorrhag‐
ing. In 2008, Wagner’s group demonstrated that the metastatic rate of experimental tumours
in a thrombocytopenic mouse model was restored when mice were retransfused with platelets
from a littermate [17]. However, if the retransfused platelets were rendered incapable of a
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secretion response, then the growth rate of metastatic tumours was again found to be low.
Thus, platelet granular contents, released from activated platelets, was responsible for the
greater metastatic potential in platelet-replete mice [17]. The authors noted a tendency for the
metastatic tumours to have fragile blood vessels and also demonstrated evidence of haemor‐
rhage in the thrombocytopenic mice. Transfusing these mice with fresh platelets rescued this
effect, allowing robust angiogenesis at the secondary lesions and permitting more metastatic
colonization of the mouse lungs[17, 53]. However, depletion of platelet granules prior to
transfusion into the thrombocytopenic mice limited the angiogenic effect, without eliminating
platelet’s ability to blood clotting process. Overall, this research suggests that the platelet
secretome is responsible for the establishment of a necessary blood supply to the tumour mass
and that this ability occurs independently from thrombus formation. In addition to this, a
recent study demonstrated impaired blood vessel density and maturation at the tumour niche
in platelet-depleted mice [67]. Thus, the pathological role that platelets can play in cancer
metastasis has now become more evident. However, the molecular mechanisms underlying
these interactions have remained somewhat elusive.
Figure 2 summarises the proposed role for platelets in enabling (A) survival of CTCs, and (B)
extravasation and metastatic growth as discussed above.
Figure 2. Simplified schematic model of platelet-mediated cancer progression. A. Platelets support cancer cell survival in
the bloodstream. CTC induce platelet aggregation and secretion. Aggregated platelets surround and protect CTC from
NK-mediated lysis via physical shielding. Platelets also release TGFβ and PDGF, which function as downregulators of
the NK-activating receptor NKGD. In addition, CTC can escape the immune surveillance through molecular mimicry
of platelets (See Section 1.2.1 for further details). B. Platelets contribute to tumour extravasation and angiogenesis. Activated
platelets interaction with tumour cells is thought to be mediated by P-selectin binding to PSGL-1 (P-selectin glycopro‐
tein ligand-1) and integrin-fibrinogen-integrin bridges. Platelet release of growth and angiogenic factors as well as pro‐
teases contributes to cancer cell extravasation and formation of new stable capillaries at the metastatic niche (See
section 1.2.2 & 1.2.3 for further details).
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3. The identity of platelet surface receptors involved in cancer progression
The surface of human platelets contains multiple receptors that help platelets to react in
response to a wide range of agonists and adhesive proteins. The roles of these receptors in
thrombosis are well established. There is also ample evidence to support the involvement of
some platelet receptors in the process of tumour cell induced platelet aggregation (TCIPA) and
cancer spreading in the bloodstream [68-72].
3.1. G Protein-Coupled Receptors (GPCR)
The seven transmembrane receptors (7TM) are well represented in platelets (Table 1) and
constitute both the major checkpoints that maintain platelets in a resting state (e.g.; PGI2
receptor/IP) and the primary mediators of the second phase of platelet activation during
thrombosis and haemostasis (e.g.; ADP receptors/P2Y1 and P2Y12; Thromboxane TXA2
Receptor/TP) [73].
Table 1. Platelet GPCRs and Ligands
3.1.1. Protease-Activated Receptors (PARs): Thrombin receptors
In haemostatic conditions, PARs drive platelet activation in response to thrombin. Thrombin
is a plasma serine-protease that is generated in response to activation of the blood coagulation
system and converts fibrinogen into fibrin, forming a mesh that serves to strengthen the
thrombus and support clot retraction. In addition, thrombin directly activates platelets causing
platelet aggregation.
Thrombin is both a platelet agonist and a pro-coagulant molecule that is required for some of
the molecular strategies used by cancer cells to progress in their lethal journey. Mice deficient
in their primary thrombin receptor, PAR-4, have a reduced ability to support metastasis
compared to wild-type mice [74].
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3.1.2. Purinergic receptor 2Y12 and 2Y1: ADP receptors
P2Y1 and P2Y12 receptors are membrane-binding sites for ADP on platelets. ADP can activate
platelets in an autocrine fashion, if released from platelet dense granules following a primary
wave of activation, or in a paracrine fashion if secreted by damaged cells at sites of vascular
injury. Some carcinomas, mainly neuroblastoma, melanoma and breast cancer cells, have been
demonstrated to be capable of secreting ADP [75, 76]. ADP scavengers such as apyrase,
efficiently impair in vitro platelet activation induced by 59M ovarian cancer cells [77], Caco-2
colon cancer cells [78], MCF-7 breast cancer cells, [79] and HeLa human cervical carcinoma
cells [80]. Experiments in mouse models of cancer provided even more direct demonstration
of the profound influence that ADP-triggered response exerts on tumour progression. When
Lewis lung tumour cells were implanted into host mice lacking the expression of P2Y12
receptors, their ability to metastasize to the lungs was disrupted [81]. In complementary
experiments, ticagrelor, a P2Y12 antagonist, succeeded in blocking tumour metastasis of B16-
F10 melanoma- and 4T1 breast cancer cells in mouse models of carcinogenesis [82]. In the same
study, ticagrelor prevent cancer cell adhesion to platelets and to endothelial cells, further
supporting a role for P2Y12-mediated platelet activation in tumour progression. Similarly,
treatment with clopidogrel, an irreversible antagonist of P2Y12 receptors protected the host
mice from pathologic osteolysis and bone loss associated with B16-F10 melanoma tumour
growth in bone [83]. Some controversy exists on whether tumour cell types generate ADP
themselves or stimulate platelets to release ADP. However, Mitrugno et al, 2014 recently
demonstrated that many tumour cells induce platelets to release ADP. Arguably, the most
impactful evidence for a role for ADP as a secondary mediator of tumour cell-induced platelet
activation comes from a study published by Battinelli and colleagues [19] who showed that
both ADP and MCF-7 breast cancer cells were separately able to trigger the release of pro-
angiogenic factors from platelet α-granules. Platelet ADP receptor antagonists reduced the
platelet response to MCF-7, suggesting that the tumour activation operates to induce the
secretory event. In addition, the impaired ability of cancer cells to transmigrate through the
endothelial barrier in Munc 13-4 deficient mice is suggestive of a strong role for ADP in
mediating this response [20]. Munc 13-4 deficient mice lack of the ability to secrete platelet
dense granules, and thus ADP and ATP release is prevented. The inability of these mice to
demonstrate detectable cancer extravasation and metastasis suggests that platelet dense
granule release is vital to cancer development.
3.1.3. TP: Thromboxane A2 receptor
Thromboxane A2, the major TP ligand, is a prostanoid generated in platelets following agonist-
induced mobilization of arachidonic acid (AA) from platelet membrane [84]. Similar to ADP,
TXA2 can activate platelets in an autocrine fashion, if released by platelets themselves, or in a
paracrine modality, if liberated in the extracellular microenvironment by malignant cancer
cells [85, 86]. Only a limited number of studies have addressed the issue of the role for platelet
TP-TXA2 molecular interplay in tumour cell induced platelet activation (TCIPA) and cancer
metastasis. However, a role for TXA2 in cancer metastasis is evident. SQ-29548, a TP antagonist,
markedly inhibits osteogenic sarcoma cells- (MG-63) induced platelet aggregation [87]. In
The Non-Thrombotic Role of Platelets in Health and Disease116
addition, TP-/- mutant mice injected with B16F1 melanoma cells present with reduced lung
colonization and mortality rate compared to wild-type littermates [88]. Finally, inhibitors of
thromboxane synthesis such as Ozagrel, BM-567 or aspirin, impair tumour induced platelet
aggregation and carcinogenesis in a number of diverse models [85, 89]. In this context, although
aspirin fails to inhibit platelet aggregation elicited in vitro by various cancer cells [69, 72, 77,
78, 90] it significantly affects platelet α-granule release of pro-angiogenic factors in response
to breast cancer cells [19].
Numerous studies from clinical trials have accumulating evidence to suggest that aspirin may
represent a potential therapeutic strategy to reduce the risk of developing cancer metastasis
and the consequent mortality [91, 92]. In a recent large meta-analysis of >17,000 patients, daily
usage of low-dose aspirin has been shown to reduce the incidence, growth and metastasis of
a number of cancers in a period of 5-6 years [93]. Overall, several platelet-dependent and
independent mechanisms of actions of aspirin as a chemo-preventive agent have been
proposed but their relevance in the treatment of cancer remains to be established [94].
3.2. Platelet Immunoreceptor Tyrosine-Based Activation Motif (ITAM) receptors
Immunoreceptors are ITAM or hemi-ITAM bearing receptors present on the platelet surface
with a conserved double (ITAM) or single (hem-ITAM) YxxL-motif in their cytoplasmic tail.
Upon receptor engagement or molecular cross-link, associated Src family kinases (SFKs)
phosphorylate the tyrosine residues (Y) within the ITAM creating a docking site for Src
homology 2 (SH2) domains of the tyrosine kinase Syk. Recruitment of Syk triggers its activation
and the formation of a LAT (linker for activation of T-cells)-signalosome localised to lipid rafts.
Among the proteins recruited to the signalosome there are cytosolic adaptors proteins (e.g.;
Grb2: growth factor receptor bound protein 2; Gads: Grb2 related adaptor protein downstream
of Shc; SLP-76: SH2 domain containing leukocyte protein of 76 kDa), and effector proteins (e.g.;
PLCγ2 and PI-3 kinase). The molecular cross-talk culminates in PLCγ2 activation which will
generate, via its lipase activity, IP3 and DAG leading to calcium mobilization and PKC
activation. Ultimately this pathway induces measurable platelet responses, including integrin
activation, TxA2 formation, and granule release (Reviewed in:[95]). The main ITAM receptors
in platelets are glycoprotein VI (GPVI), FγRIIa and C-type lectin like receptor (CLEC-2) and
their potential role in tumour cell-platelet cross-talk will be discussed below.
3.2.1. GPVI: Collagen receptor
GPVI, unique to platelets and megakaryocytes, is the primary signalling receptor for collagen.
Its ability to activate an intracellular pathway relies on its constitutive association with the
ITAM containing Fc receptor gamma receptor FcγR, [96]. GPVI is a binding-target for several
diverse fibrillar types of collagen, such as types I and III, as well as synthetic collagen-related
peptide (CRP) and snake venom proteins (e.g.; convulxin) [97]. Although GPVI is considered
an essential receptor for platelet activation, there is only limited experimental evidence
suggesting a potential involvement for this glycoprotein in tumour metastasis. In genetically
altered mice devoid of GPVI, the number of metastatic foci to lungs, following challenges with
B16F10.1 melanoma or D121 Lewis carcinoma cells, was dramatically reduced compared to
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wild type littermates [98]. However, the molecular mechanism(s) that lead to this response
remain unclear. Platelet pre-treatment with revacept, a GPVI blocker, or cancer cell treatment
with inhibitor of galectin-3, an adhesive molecule with “collagen-like” domain, resulted in a
dramatic inhibition of platelet-induced COX-2 over-expression in cancer cells [94]. Thus, GPVI
may be involved in tumour cell-induced platelet secretion and induction of epithelial mesen‐
chymal transition (EMT) in cancer cells.
3.2.2. FcγRIIa: IgG receptor
FcγRIIa is a low affinity Immunoglobulin receptor present in humans but not in mice. FcγRIIa
in humans is primarily found in platelets [99, 100]. It binds to IgG immune-complexes,
immunoglobulin-opsonised bacteria, and to auto-antibodies that target a subset of platelet
membrane proteins [101, 102]. FcγRIIa also functions as an accessory receptor of GpIb-IX-V
complex and integrin αIIbβ3 [103, 104]. Its physical association with the GpIb-V-IX complex has
been shown to be responsible for tyrosine phosphorylation within ITAM motifs via Src-family
Kinases (SFK) [104, 105]. Platelets from transgenic mice engineered to express FcγRIIa have
an improved ability to respond to stimuli resembling haemostatic events, including spreading
on fibrinogen, phosphorylation of Syk and PLCγ2, clot retraction and thrombus formation
[106]. Mitrugno et al, recently demonstrated that this platelet receptor is responsible for
mediating binding events between prostate cancer cells and platelets in vitro resulting in
tumour cell induced platelet aggregation [72].
3.2.3. CLEC-2: Podoplanin receptor
In 2006, CLEC-2 was identified as a new hemi-ITAM (single YXXL motif) platelet receptor
present as a homodimer on the platelet surface, able to activate molecular events resembling
ITAM-bearing receptors through the snake venom toxin rhodocytin [107]. Importantly
podoplanin, a sialylated transmembrane glycoprotein and the only-known physiological
ligand for CLEC-2, has been found to be expressed on certain types of human glioblastoma
(e.g.; LN319) and colon carcinoma (Colon-26) where it serves to enable TCIPA in vitro [108].
Metastatic events were found to be impaired in podoplanin knockout mice injected with
kidney tumour cells [109]. In respect to this last observation, it has been proposed that the
motile invasive behaviour of certain cancer cells relies in part on podoplanin-triggered signals.
Indeed the ectopic expression of podoplanin in oral squamous cell carcinoma positively
correlates with increased cell motility [110]. In addition, epidermal keratinocytes (MCA3D)
acquire a malignant phenotype following transfection with podoplanin [110]. All together
these observations reveal a potential role for podoplanin and podoplanin-CLEC-2 cross-talk
in cancer progression, suggesting that inhibitors of this molecular program might represent
an innovative therapeutic strategy for patients affected by certain types of cancer [44].
3.3. GPIb-IX-V Complex: VWF receptor
The GPIb-IX-V complex is a member of the leucine-rich repeats (LLRs) family of adhesive
multimeric proteins consisting of two GPIbα subunits disulphide-linked to two GPIbβ
subunits and associated non-covalently with GPIX and GPV protein on the platelet surface
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[111]. This complex plays an essential role in mediating the initial adhesion of platelets to VWF
at sites of vascular injury in high shear conditions (above 1000s-1), and in triggering activation
of integrin αIIbβ3 [112, 113]. Upon ligand engagement, the GpIb-X-V complex recruits cyto‐
plasmic SFKs and PI3Ks via the GpIbα cytosolic tail, leading to calcium release and integrin
activation. Alternatively, it can couple with the FcγRIIa chain to trigger ITAM-like signalling
[104, 114]. VWF, a major but not unique GpIbα ligand, is a large multimeric adhesive glyco‐
protein associated with collagen in the subendothelial matrix. Importantly, following activa‐
tion, it can also be released by Weibel-Palade bodies in endothelial cells and α-granules in
platelets [115].
The role of GpIbα in cancer metastasis has been subject of many studies that converge in
contradictory results. GPIbα is present on some cancer cell surfaces and appears to play a
role in cancer cell-induced platelet aggregation [116]. However, the expression of GpIbα on
the surface of cancer cells is not common [70, 117]. Contradictory results have been reported
in in  vivo  studies.  Reduced melanoma metastasis  to  the lungs is  observed in mice defi‐
cient  in  GpIb-IX-V complex  [118].  In  contrast,  administration of  anti-GPIbα monovalent
antibodies in melanoma-bearing mice resulted in a strong enhancement of lung metasta‐
sis [119].  Similarly, an increased metastatic potential was observed in mice lacking VWF
[120]  but  not  in  mice  treated  with  anti-VWF  antibodies,  which  were  protected  from
metastasis  [121].  Thus,  the role  of  GpIb in the cancer cell-platelet  loop remains unclear,
making it object of further investigation.
3.4. Platelet integrins: αIIbβ3
Integrin αIIbβ3 is the most abundant cell adhesion molecule on the platelet surface (approxi‐
mately 80,000 receptors per platelet), with an additional pool of protein that can be recruited
from internal α-granule membranes upon platelet activation [122]. αIIbβ3 exists in a low affinity
or inactive state in circulating, un-activated platelets and undergoes conformational changes
following platelet stimulation by soluble agonists such as thrombin. Conformationally active
integrin displays an increased affinity for its endogenous ligands: principally plasma fibrino‐
gen and VWF. This interaction stabilises the adhesion of platelets to the extracellular matrix
and permits cross-linking of activated platelets, causing aggregation and haemostatic plug
formation. Importantly, ligand binding to αIIbβ3 enables “outside-in” molecular circuits, which
lead to thrombus stability and fibrin clot retraction [123, 124]
Lacking enzymatic activity, integrins must cooperate with other cytoplasmic proteins to
trigger intracellular signals. Importantly, recent investigation has revealed the capacity of αIIbβ3
to associate with molecular mediators of ITAM-bearing receptors. In this scenario, FcγRIIa has
been proposed as a key molecular partner or accessory receptor for αIIbβ3 [102, 103]. FcγRIIa
is recruited to activated αIIbβ3 microclusters enriched in SFK, leading to the phosphorylation
of FcγRIIa-ITAM sequence that provides a link to Syk. As yet however, the mechanism and
stoichiometry of the interaction between αIIbβ3 and FcγRIIa remains obscure.
Integrin αIIbβ3 is the adhesive molecule which has been most explored in in vivo models of
haematogenous metastasis and in in vitro models of TCIPA [70]. A monoclonal antibody (10E5)
directed against αIIbβ3 inhibits the ability of tumour cells to bind to platelets [121]. The same
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antibody is also able to reduce the number of metastatic foci to lungs in a mouse model of
tumour metastasis using colon carcinoma CT26 cells [125]. Similarly, a reduction in the extent
of tumour cell colonisation of the lungs was also observed in integrin β3-/- mice injected with
B16F10 melanoma cells [126]. These findings have then been confirmed in a number of
additional studies [70]. In addition, αIIbβ3 inhibitors modulate TCIPA elicited by diverse human
tumour cells, including colon carcinoma, cervical and vaginal melanoma and breast cancer [72,
90, 116, 127]. Moreover, abciximab (anti-αIIbβ3 monoclonal blocking antibody) inhibits the
release of pro-angiogenic factors such as VEGF, from the platelet α-granules by MCF-7 breast
cancer cells [66] indicating that integrin αIIbβ3 activation is necessary to support platelet
activation and platelet secretion. Taken together these results highlight αIIbβ3 as attractive
target for future anti-metastatic therapies.
4. Platelet granules and their role in cancer progression
Although considerable progress has been made in understanding how platelets interact with
cancer cells to initiate an interdependent relationship, little is known about how that relation‐
ship develops. Following platelet association with tumour cells, platelet secretion of dense
granules [72], and α-granules [19, 66] ensues and the resulting platelet releasates contribute to
tumour progression. As yet, however, very little is known about the potential “intrinsic” ability
of cancer cells to induce platelet granule release. Moreover, the precise molecular orchestrators
of this phenomenon remain completely unknown. It is likely that, like platelet interactions
with bacterial micro-organisms, different cancer cell types may interact in different ways with
platelets [128]. Ultimately, however, the ability of tumour cells to engineer the release of
platelet-stored cytokines and bioactive molecules appear to be a key component of the critical
interaction that remains to be elucidated.
4.1. α-granules
α-granules are the most abundant granule population in platelets (50-80 per platelet) present‐
ing a heterogeneous morphology, size and luminal content as well as protein repertoire [64,
129, 130]. Electron tomography of platelet cryo-sections revealed the presence of 3 major
different subtypes of α-granules based on average size and contents: 1) 200-500 nm spherical
α-granules featuring an electron dense core and eccentrically localised multimeric VWF
tubules; 2) multivesicular 100-200 nm granules displaying a multitude of free luminal mem‐
brane vesicles; and 3) 50 nm- tubular α-granules rich in fibrin-like structures [129]. Importantly,
there seems to be also two further dimension of complexity with regard to (i) α-granules
protein content and (ii) speed of release.
Immunofluorescence and immuno-electron microscopy data from certain laboratories show
distinct localizations for pro- and anti-angiogenic factors in platelet α-granules, indicating that
proteins are segregated among α-granules during their initial synthesis, according to their
biological function [60, 130]. This separate packaging then permits a differential secretory
behaviour, in terms of type of protein released in response to different stimuli [19, 64, 130]. Ma
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and colleagues first demonstrated the ability of platelets to release their content in a “thematic”
way [131]. VEGF (pro-angiogenic), but not endostatin (anti-angiogenic) was selectively
released upon platelet stimulation with PAR-4 agonist while an opposite response was
observed following platelet exposure to a thrombin receptor ligand [131]. However, to date,
the knowledge of the molecular mechanism(s) orchestrating the selective platelet release
remains elusive [129]. It must be noted that recent studies show activation of different PARs
elicit similar releasate patterns and cargoes within the α-granules are randomly packaged,
however there are indications that spreading platelets are capable of sorting and separating
α-granules subtypes [132-134]. Either way, it will be intriguing to address whether this
classification of granules is physiologically meaningful and if it changes during pathological
events such as cancer.
α-granules are functionally pleiotropic, meaning that they can serve different and significant
functions [135]. Thus, the release of their contents can be pivotal in establishing the nature of
the surrounding microenvironment [135]. More than 300 molecules have been shown to be
released from activated platelets [136], which differ in their origin. Some components may be
synthesized in the megakaryocyte whereas others are scavenged from plasma [135]. The
contents of platelet α-granules also differ in their function [10, 135, 137]. Functionally, α-
granule contents can be divided in the following categories: 1) adhesive molecules (e.g.;
fibrinogen, fibronectin, vitronectin, thrombospondin, VWF, P-selectin, αIIbβ3) which mediate
homotypic (platelet-platelet) and heterotypic (platelet-endothelial cells) interactions and
subsequent clot formation (primary heamostasis) ; 2) coagulation factors (e.g.; fibrinogen, pro-
thrombin, Factor V, Factor VII) which play a crucial role in the stabilization of the haemostatic
clot; 3) fibrinolytic agents (e.g. plasminogen activator inhibitor-1 (PAI-1)) which are important
for clot remodelling; 4) growth factors (e.g.; PDGF, VEGF, EGF, TGFβ) which can contribute
to wound healing, angiogenesis, chemotaxis and cell proliferation; 5) pro-angiogenic and anti-
angiogenic factors (e.g.; angiopoietin, VEGF, endostatin, angiogenin, angiostatin; and tissue
inhibitors of metalloproteases 1 and 4 (TIMP1 and TIMP-4) which regulate the de novo
formation of blood vessels; 6) tissue-remodelling factors (e.g. MMPs, TIMPs and disintegrin
metalloproteinases (ADAMs)) which allow structural remodelling of the ECM and the
solubilisation and activation of a variety of growth factors tethered in an inactive form to the
proteoglycans of the ECM ; 7) pro-inflammatory factors which include a pool of chemokines
(e.g.; CXCL1 (GRO-α), CXCL4, CXCL5 (ENA-78), CXCL7 (NAP-2), CXCL8 (IL-8), CXCL12
(SDF-1a), CCL2 (MCP-1), CCL3 (MIP-1a), CCL5 (RANTES), CCL17 (TARC)), which induce
recruitment, activation, chemokine secretion and differentiation of other cells, involved in
wound healing, from the circulation [10, 135].
Importantly, all these molecules have the potential to contribute to the progression of cancer.
Moreover, the platelet granule contents may change as a consequence of the host being infected
with a cancer [61]. This leads to the intriguing possibility that certain cancer cells can prime
circulating platelets with active cytokines, tailored to permit tumour cell survival at a meta‐
static site. Alternatively, tumour cells may upregulate the levels of select platelet cytokines to
enable avoidance of an immune response and thus enhance CTC survival in a host. A more
complete understanding of the platelet-tumour cell interdependence will be critical for the
design of therapeutic interventions to supress cancer progression.
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4.2. Platelet dense granules
Each platelet contains just 3 - 8 dense granules, which measure approximately 250 nm in
diameter  [138].  They  concentrate  a  number  of  small  molecules  including:  1)  ions  (e.g.;
calcium, magnesium, phosphate, pyrophosphate); 2) nucleotides (e.g.; ADP, ATP, GTP and
GDP). 3) transmitters (e.g.; serotonin, epinephrine, histamine), and 4) membrane proteins
which are also found in lysosomes (e.g.; LAMP-2). Serotonin and ADP function as secondary
mediators, or positive enhancers of the platelet aggregation response. Interestingly, about
50% of platelet ADP is stored in platelet dense granules and cannot be refilled following
platelet  activation.  In contrast,  the metabolic  pool  of  adenine nucleotides,  housed in the
platelet  cytosolic  compartment,  can  be  synthesized  but  not  released  [139].  Serotonin,  is
instead  sequestered  by  platelets  from  plasma  and  released  into  the  circulation  upon
activation where it can act as both an autocrine and a paracrine mediator [140]. The autocrine
function serves to  amplify the platelet  response through engagement of  the Gq-coupled
5HT2A receptor on platelet surface, whereas the paracrine effect contribute to the modula‐
tion of the vascular tone, normally inducing vasoconstriction to limit the blood flow and
reduce  blood  loss  at  sites  of  vascular  injury  [138].  Calcium  found  in  dense  granules
constitutes from 60 to 70% of total calcium mobilised in platelets. [140-142]. The function
of the calcium released by platelets into the extracellular space is uncertain, however it has
been  speculated  that  it  may  play  a  role  in  facilitating  the  binding  of  the  extracellular
adhesive proteins to their receptors on platelets [138].
4.3. Lysosomes
Lysosomes constitute a less characterised granule type present in platelets in marginal number
(0-1 per platelet). They are packaged with cathepsins, carboxypeptidases, β-hexosaminidase,
acid phosphatases, enzymes for hydrolyzing various sugars and aryl sulfatases. CD63 and
LAMP2 are membrane-bound molecules normally used as markers of lysosomes [138].
Though the exact function of lysosomes in platelets is not known, they are thought to be
involved in dissolution of the clot [10].
5. Platelet secretion and the progression of cancer
In 1984 Boneu et al., first reported the presence of degranulated platelets, characterised by low
levels of ADP and serotonin, in patients with malignant solid tumours [143] suggesting that
platelet secretion was a critical event in tumour growth. Wagner’s research group subsequently
showed that platelet secretions continuously support tumour vascular homeostasis by
regulating the stability of tumour vessels [17]. However, the exact identity of platelet-derived
factors responsible for tumour vessel protection remains unknown.
A potential role for ADP and serotonin, released by platelet dense granules, has been proposed
[63, 72]. Platelet dense granule secretion of adenine nucleotides in a tumorigenic microenvir‐
onment may be key to tumour cell extravasation and to the formation of metastatic foci. One
mechanism downstream from this phenomenon has been uncovered [20]. Platelet-derived
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ATP binds to P2Y2 receptors on endothelial cells triggering a signalling cascade that culminates
in the disaggregation of the endothelial barrier. Moreover, platelet-derived ADP can also
participate in tumour cell-induced platelet aggregation [144], a strategy adopted by several
tumour cell lines to evade the immune system and overcome high arterial shear stress during
the haematogenous journey [28].
Cancer  cells  can  also  induce  platelet  release  of  matrix  metalloproteinases  (MMPs)  and
cytokines from α-granules  [145].  These bioactive molecules  can destroy the extracellular
matrix barrier and promote invasion and tumour extravasation. Among the MMPs, MMP-2
has  been  shown  to  be  autocrine  mediator  of  TCIPA  elicited  by  human  fibrosarcoma
HT-1080, lung carcinoma A549, breast adenocarcinoma MCF7 and colon adenocarcinoma
Caco-2 cells [68, 69, 78].
Platelet release of adhesive proteins such as αIIbβ3, P-selectin, and fibrinogen can also poten‐
tially support and stabilise adhesive interaction of tumour cells with both platelets (platelet-
cancer aggregate) and endothelial cells, favouring tumour cells transmigration across the
endothelial barrier. Similarly, the release of coagulation factors can prompt the conversion of
fibrinogen into fibrin which will strengthen the heterotypic platelet-cancer aggregate and
ensure its survival and safe docking at the metastatic site [146, 147]. As discussed previously,
platelets contain both pro- and anti-angiogenic factors that can be differentially released to
ensure optimal tumour angiogenesis [19, 63]. Moreover, in animals bearing malignant
tumours, platelets can be conditioned to selectively store and release regulators of angiogenesis
[60]. Importantly, it has been shown that platelets are not just simply transporters of tumour-
derived pro-angiogenic molecules. In a mouse model of metastasis, Kerr and colleagues have
demonstrated the ability of platelet to sequester diverse tumour-derived cytokines and to
safely transport them to a distant metastatic niche for release [61]. This excellent strategy seems
to be engineered by cancer cells to hijack important pro-metastatic and pro-inflammatory
proteins and impede their degradation in plasma. It is noteworthy that this emerging concept
of platelets as carriers of tumour-derived proteins can provide a window to the needs of cancer
cells and guide the clinician towards an optimal therapeutic approach. Interestingly, in the
study by Kerr and colleagues [61], granulocyte colony-stimulating factor (G-CSF) was found
to be abundantly released in the plasma of tumour-bearing mice by both platelets and cancer
cells. The same result was also separately observed by Wagner’s group who subsequently
uncovered a potential role for G-CSF in the formation of neutrophil extracellular traps (NETs)
and cancer-associated thrombosis [148]. NETs are suggested to facilitate tumour metastasis by
trapping circulating tumour cells [149].
Once recruited by the circulating tumour cells, platelets can release a plethora of growth factors
including platelet derived growth factor (PDGF-BB) and transforming growth factor beta
(TGFβ), which can contribute to the inflammatory state often associated with cancer [10]. In
this context, TGF-β derived from platelet α-granules profoundly impacts tumour metastasis
and survival by enhancing an epithelial-to-mesenchymal transition (EMT), via activation of
the TGFβ/Smad and NF-KB signalling pathways in tumour cells, and suppressing tumour cell
NK-mediated lysis [16, 35]. EMT is a program which enables cancer invasiveness and dissem‐
ination [150].
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A summary flowchart of platelet secretion events in cancer is presented in Figure 3 summa‐
rizing 30 years of the causal evidence linking secretion and tumour survival characteristics.
Despite these recent discoveries of platelet secretion affecting cancer cells, and vice versa, the
precise molecular mediators at play between tumour cells and platelets are not yet fully
understood. The use of anti-platelet agents is currently emerging as potential treatment of
malignancy and tumour-derived thrombosis [63, 151]. However, this use of platelet inhibitors
to improve cancer prognosis and reduce the risk of fatal metastasis must take into account the
delicate balance between inhibiting platelet activation and the associated risk of bleeding. The
identification of the precise molecular pathways in platelets in response to activation by cancer
cells may permit greater progress in this area.
Figure 3. Flowchart highlighting the potential role of platelet-released molecular mediators in neoplastic progression.
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